New hope for advanced cancers? first human trial of XL309 begins

NCT ID NCT05932862

Recruiting now Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a new drug called XL309, alone or with another drug (olaparib), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 429 adults will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XL309 (ISM3091) and olaparib
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not work or could have unexpected side effects. It is too soon to know if it will benefit patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm neoplasm ovarian cancer pancreatic neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Exelixis Clinical Site #1
RECRUITING

Houston, Texas, 77030, United States
Exelixis Clinical Site #10
WITHDRAWN

Kansas City, Missouri, 64111, United States
Exelixis Clinical Site #11
RECRUITING

Germantown, Tennessee, 38138, United States
Exelixis Clinical Site #12
WITHDRAWN

Fountain Valley, California, 92708, United States
Exelixis Clinical Site #13
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Exelixis Clinical Site #14
RECRUITING

Rochester, Minnesota, 55905, United States
Exelixis Clinical Site #15
RECRUITING

Jacksonville, Florida, 32224, United States
Exelixis Clinical Site #16
RECRUITING

Tampa, Florida, 33612, United States
Exelixis Clinical Site #2
WITHDRAWN

Houston, Texas, 77030, United States
Exelixis Clinical Site #3
RECRUITING

San Antonio, Texas, 78229, United States
Exelixis Clinical Site #4
RECRUITING

Austin, Texas, 78758, United States
Exelixis Clinical Site #5
RECRUITING

New York, New York, 10029, United States
Exelixis Clinical Site #6
RECRUITING

Nashville, Tennessee, 37203, United States
Exelixis Clinical Site #7
RECRUITING

Cleveland, Ohio, 44106, United States
Exelixis Clinical Site #8
RECRUITING

Orlando, Florida, 32827, United States
Exelixis Clinical Site #9
RECRUITING

New Brunswick, New Jersey, 08901, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.